ArticleTargeted oncology2019

Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.

Yiming Zhao et al.PubMed ↗Publisher ↗

No numbers read from the abstract.